Holen Sie sich die Stockscreener-App
175.97
3.35%
5.70
Handel nachbörslich:
177.00
1.03
+0.59%
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed (INSM) Surpasses Revenue Expectations with Strong Growth - GuruFocus
Insmed Maps Aggressive 2026: New Lung Disease Drug, Pipeline AdvancesInsmed (NASDAQ:INSM) - Benzinga
Insmed posts early 2025 revenue beating consensus (INSM:NASDAQ) - Seeking Alpha
Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating - TipRanks
Insmed jumps after forecasting preliminary 2025 revenue above estimates - TradingView — Track All Markets
Insmed Incorporated Provides Revenue Guidance for the Full Year 2025 - MarketScreener
Insmed shares jump on robust BRINSUPRI rollout and ARIKAYCE outperformance - MSN
Insmed (INSM) Projects Arikayce Revenue of $450M-$470M for FY26 - GuruFocus
INSM Projects Brinsupri Revenue to Reach $172.7 Million by FY25 - GuruFocus
Insmed stock rises after strong BRINSUPRI launch, ARIKAYCE revenue beat By Investing.com - Investing.com UK
Insmed reports strong Q4 revenue for BRINSUPRI and ARIKAYCE By Investing.com - Investing.com UK
Insmed Inc Provides Business Update at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - Yahoo Finance
Insmed chief legal officer Smith sells $549k in stock By Investing.com - Investing.com Canada
Why Insmed Incorporated (IM8N) stock remains top ratedVolume Spike & Short-Term Trading Opportunity Alerts - ulpravda.ru
Insmed chief medical officer Flammer sells $2.8m in stock By Investing.com - Investing.com Canada
Insmed chief medical officer Flammer sells $2.8m in stock - Investing.com
Insmed COO Adsett sells $747k in stock By Investing.com - Investing.com Canada
Insmed CFO Bonstein sells $808,733 in stock - Investing.com
INSMED Executives Conduct Series of Stock Transactions - TradingView — Track All Markets
Insmed Insider Sold Shares Worth $549,494, According to a Recent SEC Filing - MarketScreener
Published on: 2026-01-09 00:10:22 - ulpravda.ru
Analysis Recap: Is Insmed Incorporated stock a good choice for value investors2025 Fundamental Recap & AI Powered Market Entry Strategies - ulpravda.ru
Will Insmed Incorporated stock outperform tech sector in 20252025 Market Outlook & Real-Time Stock Price Movement Reports - ulpravda.ru
Will Insmed Incorporated stock recover faster than peersJuly 2025 Summary & Long-Term Investment Growth Plans - ulpravda.ru
Published on: 2026-01-08 19:10:10 - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Jim Cramer on Insmed: "This One Is Worth Keeping an Eye On" - Finviz
Jim Cramer on Insmed: “This One Is Worth Keeping an Eye On” - Insider Monkey
RBC Lifts Price Target on Insmed to $197 From $195, Keeps Outperform Rating - MarketScreener
How analysts rate Insmed Incorporated stock todayInterest Rate Changes & Affordable Trading Techniques - ulpravda.ru
Non-Cystic Fibrosis Bronchiectasis Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed - Barchart.com
What Catalysts Are Quietly Shifting The Narrative For Insmed (INSM)? - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Insmed Insider Sold Shares Worth $15,293,422, According to a Recent SEC Filing - marketscreener.com
INSM: UBS Lowers Price Target While Maintaining 'Buy' Rating | I - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed ... - Bluefield Daily Telegraph
UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating - MarketScreener
Insmed stock price target reiterated at $195 by Leerink on Brinsupri launch - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Market Review: Why Insmed Incorporated IM8N stock remains top ratedAnalyst Downgrade & High Conviction Investment Ideas - moha.gov.vn
Allspring Global Investments Holdings LLC Decreases Holdings in Insmed, Inc. $INSM - MarketBeat
INSM Stock Up 78% in 6 Months: Here's What You Need to Know - Finviz
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Insmed Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Calamos Advisors LLC Acquires 12,263 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insmed Incorporated (INSM) And Encourages Investors to Connect - ACCESS Newswire
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Insmed's chief medical officer sells $2.97 million in stock - MSN
Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INSM Quantitative Stock Analysis - Nasdaq
Rice Hall James & Associates LLC Sells 7,103 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
A Closer Look at Insmed's Options Market DynamicsInsmed (NASDAQ:INSM) - Benzinga
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
NASDAQ adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22 - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Investors to Inquire about Securities Investigation - ACCESS Newswire
Insmed (FRA:IM8N) EV-to-OCF : -39.13 (As of Dec. 25, 2025) - GuruFocus
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
5.47%
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):